When was Entegrion founded?

Entegrion was founded in 2002 and raised its 1st funding round 5 years after it was founded.

Where is Entegrion located?

Entegrion is headquartered in Durham, United States. It is registered at Research Triangle Park (United States).

How many employees does Entegrion have?

As of Sep 30, 2026, the latest employee count at Entegrion is 11.

Is Entegrion a funded company?

Entegrion is a funded company, having raised a total of $30.5M across 15 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 08, 2007.

When was the latest funding round of Entegrion?

Entegrion's latest funding was a $***** Series B round on Jul 05, 2022, with participation from 0 investor. Its primary sector is Hematology. In United States, the Hematology sector has seen $594M in funding in 2026 to date.

Where does Entegrion rank among its competitors?

Entegrion ranks 4th amongst 31 active competitors, of which 8 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was MedicQuant ApS, which secured $81.9K in Jul, 2023.

Who are the top competitors of Entegrion?

Entegrion's top competitors include Diagnostica Stago, Coag-Sense and Accriva Diagnostics. Among them, MedicQuant ApS secured the most recent funding round in July, 2023.

Entegrion - 2026 Company Profile, Team, Funding & Competitors

Entegrion is a series B company based in Durham (United States), founded in 2002 by Arthur Bode. It operates as a Provider of hemostasis and fluid replacement products. Entegrion has raised $30.5M in funding. The company has 31 active competitors, including 8 funded and 5 that have exited. Its top competitors include companies like Diagnostica Stago, Coag-Sense and Accriva Diagnostics.

Company Details

Entegrion is a provider of hemostasis and fluid replacement products. Products include Portable Coagulation Monitor (PCM), Multi-Functional Resuscitation Fluid (MRF), PCM provides data faster to doctors and directly to first responders. It also offers a hemostatic patch and Stasix particles that can be loaded with imaging and highly cytotoxic materials for targeted delivery to areas of vascular distress. The Portable Coagulation Monitor is based on Thromboelastography and has the potential for use in emergency medicine, obstetric and general surgery applications, and in pre-hospital emergency medicine.

Website: entegrion.com
Social
Email ID: *****@entegrion.com
Registered Address: Research Triangle Park (United States)

Key Metrics

Founded Year

2002

Location

Durham, United States

Stage

Series B

Total Funding

$30.5M in 15 rounds

Latest Funding Round

Series B, Jul 05, 2022, $*****

Investors

Sway Ventures & 5 more

Ranked

4^th among 31 active competitors

Employee Count

11 as on Sep 30, 2026

Similar Companies

Diagnostica Stago & 33 more

View Entegrion's full profile

Entegrion is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ENTEGRION INC CIN: 1392253 , United States, Active		$1M - $5M (As on Oct 19, 2009)	-	-
Entegrion, Inc. CIN: 01-0708744 , United States, Active	Mar 28, 2004	-	4 (As on Dec 31, 2020)	-

Entegrion has raised a total funding of $30.5M over 15 rounds. Its first funding round was on Mar 08, 2007. Entegrion has 6 institutional investors.

Here is the list of recent funding rounds of Entegrion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 05, 2022	8202231	Series B	1728744	8749997	2027648	4131550
May 15, 2019	3470239	Series A	5435435	5270191	6671813	6078768
Jul 31, 2012	8798557	Grant (prize money)	3048433	8259666	5799329	ONR

Access funding benchmarks and valuations. Sign up today!

View details of Entegrion's funding rounds and investors

The founders of Entegrion is Arthur Bode.

Here are the details of Entegrion's key team members:

Arthur Bode: Co-Founder of Entegrion.

Entegrion's Board of Directors

Entegrion's board has 40 active members. Patrick Nash, Richard Kendall, Michael Galiger, R. Les Brownlee, J. True Martin, William Corbitt, Patrick F. Nash, John B Mowell, Thomas L Edwards, J True Martin, William S Corbitt III, Patrick F Nash, John B. Mowell, Stephen R Petteway, Jr., Robert Capps, Jeffery C. Basham, Richard E. Martin, Albert Valada, Brian Gibler, Joseph DaCorta, W Brian Gibler, Ronald Sacher, Romie Brownlee, E. S. Eskridge, Jr., Thomas L. Edwards, James T. Martin, Norman E. Thagard, Les Brownlee, Susan Reyer, J. True Martin, Christopher Rumana, William S. Corbitt, III, E. Stan Eskridge, Jr., J. True Martin, Dr., John Mowell, Norman E Thagard, Thomas Edwards, Stephen R. Petteway, Jr., Pierre Noel and Richard Martin are independent board members.

Here is the list of Entegrion's board of directors:

Name	Type	Representing	Status	Duration
Patrick Nash	Independent board member	-	Current	11y 0m
lcmwjwz	Independent board member	-	Current	7y 8m
ravmrxo	Independent board member	-	Current	1y 9m
jup{zd{	Independent board member	-	Current	8y 2m
dceyyfq	Independent board member	-	Current	1y 7m
wrzljyu	Independent board member	-	Current	8y 9m
bpclvmf	Independent board member	-	Current	1y 5m
nlnhjmb	Independent board member	-	Current	2y 8m
lilljal	Independent board member	-	Current	7y 4m
wto{rzr	Independent board member	-	Current	6y 6m
hbzzhqo	Independent board member	-	Current	4y 2m
okmagld	Independent board member	-	Current	6y 5m
peltdkp	Independent board member	-	Current	9y 9m
oqr{hmv	Independent board member	-	Current	5y 2m
xkrxgo{	Independent board member	-	Current	2y 2m
zkpzmcr	Independent board member	-	Current	7y 7m
xioheqf	Independent board member	-	Current	2y 8m
vjoiwey	Independent board member	-	Current	7y 8m
tfwayic	Independent board member	-	Current	2y 5m
lrdviec	Independent board member	-	Current	9y 1m
ikr{sdl	Independent board member	-	Current	8y 9m
bzhenzu	Independent board member	-	Current	5y 1m
zz{ewyl	Independent board member	-	Current	1y 2m
avdsdjo	Independent board member	-	Current	6y 9m
kjwlayl	Independent board member	-	Current	9y 1m
aifqhtg	Independent board member	-	Current	9y 9m
gldqox{	Independent board member	-	Current	2y 7m
btgbujp	Independent board member	-	Current	4y 8m
qxrxhqf	Independent board member	-	Current	9y 8m
rqwvczc	Independent board member	-	Current	3y 7m
erxk{zo	Independent board member	-	Current	1y 9m
ktaiwif	Independent board member	-	Current	3y 3m
lyo{dmp	Independent board member	-	Current	7y 8m
duxpyqh	Independent board member	-	Current	8y 6m
jfmzybc	Independent board member	-	Current	4y 7m
nxqyrmo	Independent board member	-	Current	1y 1m
{oylpx{	Independent board member	-	Current	7y 6m
iyzghop	Independent board member	-	Current	5y 6m
xajgh{h	Independent board member	-	Current	1y 3m
q{pykty	Independent board member	-	Current	3y 2m

View details of Entegrion's Founder profiles and Board Members

Entegrion's employee count trend

Entegrion has 11 employees as of Sep 26. Here is Entegrion's employee count trend over the years:

Uncover Entegrion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Entegrion include Diagnostica Stago, Coag-Sense and Accriva Diagnostics. Here is the list of Top 10 competitors of Entegrion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Diagnostica Stago 1998, Paris (France), Acquired	Portfolio of products for hematology and hemostasis	-	-	55/100
2nd	Coag-Sense 2008, San Francisco (United States), Series A	Innovating coagulation monitoring with accurate, accessible PT/INR testing solutions	$5M	DSC Investment, Korea Investment Holdings ... & 1 others	51/100
3rd	Accriva Diagnostics 2009, San Diego (United States), Acquired	Develop products/systems for diagnostics.	$144M	Kleiner Perkins, Bay City Capital & 3 others	45/100
4th	Entegrion 2002, Durham (United States), Series B	Provider of hemostasis and fluid replacement products	$30.5M	Sway Ventures, Defense.gov & 4 others	43/100
5th	Enzyre 2016, Nijmegen (Netherlands), Series A	Developer of smart diagnostics devices for blood coagulation analysis	$11.9M	Novalis Biotech, Oost NL & 3 others	38/100
6th	MedicQuant ApS 2019, Aarhus (Denmark), Seed	Provider of diagnostic kit for blood anticoagulants	-	Waarst Holding, BioInnovation Institute & 2 others	38/100
7th	Medical Ingenuities 2011, Wheaton (United States), Series A	Developer of radial artery occlusion devices for hematology treatments	$997K	cultivate(MD), Genesis & 3 others	36/100
8th	ClotPro 2017, Munich (Germany), Acquired	Provider of device for coagulation diagnostic	-	-	32/100
9th	Perosphere 2011, Mount Kisco (United States), Acquired	Anticoagulant reversal agent and small molecules to prevent allergic reactions, traumatic brain injury.	$9.36M	Connecticut Innovations	32/100
10th	Microvisk 2004, Saint Asaph (United Kingdom), Series B	Provider of a handheld device to monitor blood clots	$16.6M	Finance Wales, Origin Capital & 8 others	32/100